Ikuo Hirano, MD, provides his academic expertise in esophageal swallowing physiology and clinical experience to improve the management of patients with eosinophilic esophagitis (EoE). To distinguish EoE from a myriad of diagnoses, Dr. Hirano shares his experience and discusses the latest evidence-based recommendations to assess and diagnose patients with EoE. He reviews common symptoms and food triggers and how to identify adaptive behaviors that can mask patients living with EoE. He shares an overview of ongoing unmet clinical needs along with an in-depth review of standard of care treatment and emerging therapies. To facilitate integration into practice, the activity is augmented by video clips and case discussions.
NOTE: This activity includes discussion of dupilumab as an investigational medication for the treatment of patients with EoE. After this activity was finalized, dupilumab was approved by the US Food and Drug Administration for: “treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis.”
Course Credit:
1.00 AMA PRA Category 1 CreditTM
1.00 ANCC Contact Hour
0.50 Pharmacology Hours
Dates:
Opens: 2022-06-02
Closes: 2023-06-02
Target Audience:
This activity was developed for gastroenterologists, allergists, immunologists, pediatric gastroenterologists, pediatric allergists/immunologists, specialty NP/PAs, and other healthcare professionals who have an interest in Eosinophilic Esophagitis (EoE).
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme
Accreditation and Certification
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
A maximum of 1.00 contact hour, including 0.50 pharmacology hours, may be earned for successful completion of this activity.
Additional Content Planners
Eugene Cullen, MD (Peer Reviewer)No significant relationships to disclose.
Heather M. Jimenez, FNP-C (Nurse Reviewer)
No significant relationships to disclose.
Sunali Wadehra, MD (Medical Writer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
Ikuo Hirano, MD
Professor of Medicine
Division of Gastroenterology and Hepatology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Presenting Faculty
Learning Objectives
- Summarize the latest evidence-based recommendations for assessing and diagnosing patients with EoE
- Evaluate the new and emerging clinical data on pharmacologic therapies for EoE
- Apply evidence-based principles to designing a treatment plan for patients with EoE
Faculty Disclosures
Ikuo Hirano, MD
Consultant: Allakos, Adare, Arena, AstraZeneca, Bristol Meyers Squibb, Celgene, Ellodi, Nexstone, Phathom, Regeneron, Sanofi, Shire, Takeda
Research Support: Adare, Allakos, Arena, AstraZeneca, Bristol Meyers Squibb, Celgene, Ellodi, Regeneron, Sanofi, Shire, Takeda
Speakers Bureau: Regeneron, Sanofi